AGP Executive Report
Last update: 4 hours agoObesity drug deal: Novo Nordisk agreed to pay Hengrui Pharma up to US$2.6bn for HRS-1596, a phase 1-ready oral GLP-1/GIP dual agonist with potential once-weekly dosing—Novo gets rights worldwide except mainland China, Hong Kong, Macao and Taiwan; the pact includes US$300m upfront plus milestone payments and royalties. Heart health push: On World Heart Day, Hong Kong’s Department of Health urged residents to prevent cardiovascular disease with balanced diet, exercise, and no smoking or drinking, and to use government preventive care programmes. CVD in Asian communities: A new clinical guide highlights high CVD burden among Asian Americans and calls for earlier screening for risks like diabetes and heart disease. Rare but serious case: A Macau report describes intramural hematoma of the esophagus after a man on daily aspirin developed chest pain and vomiting blood—an example of how some dangerous-looking symptoms can still heal without surgery. Public health alerts: Hong Kong’s CHP reported four Legionnaires’ disease cases and reminded higher-risk groups to maintain water systems properly. Community wellbeing: A Macau survey found 36.2% of residents volunteered in the past year, with participation highest among ages 18–24. Safety on campus: FEHD stepped up inspections of school lunch box suppliers, with samples reported satisfactory.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
